Lamotrigine + Olanzapine for Treatment-Resistant OCD
Lamotrigine augmentation shows evidence of efficacy for treatment-resistant OCD, while olanzapine has limited and conflicting evidence; however, neither combination (lamotrigine + olanzapine together) has been studied, and current guidelines prioritize other augmentation strategies first.
Evidence-Based Treatment Hierarchy for SSRI-Resistant OCD
When first-line SSRI therapy fails after 8-12 weeks at maximum tolerated doses, the following augmentation strategies are supported by guidelines 1:
Tier 1: Strongest Evidence
- CBT augmentation (largest effect size compared to antipsychotic augmentation)
- Clomipramine augmentation (superior to quetiapine in head-to-head trial, though carries risk of drug interactions, seizures, arrhythmia, and serotonin syndrome) 1
Tier 2: Antipsychotic Augmentation
- Risperidone and aripiprazole have meta-analytic evidence of efficacy 1
- Important caveat: Only one-third of SSRI-resistant patients show clinically meaningful response 1
- Critical monitoring needed: Weight gain and metabolic dysregulation are significant concerns 1
Tier 3: Glutamatergic Agents
The guidelines specifically mention glutamatergic medications as emerging augmentation options 1:
- N-acetylcysteine has the largest evidence base (3 of 5 RCTs positive)
- Memantine has demonstrated efficacy in multiple trials
- Lamotrigine is mentioned among glutamatergic agents with "some evidence of efficacy"
Specific Evidence for Your Question
Lamotrigine Augmentation
Lamotrigine alone as augmentation shows promise with two double-blind RCTs demonstrating efficacy:
- 12-week trial: 100mg lamotrigine produced significant reductions in Y-BOCS obsessions (p=0.01), compulsions (p=0.005), and total scores (p=0.007) with effect size of 0.54 2
- 16-week trial: 100mg lamotrigine showed highly significant improvements in obsessions (p<0.0001), compulsions (p<0.0001), and total Y-BOCS (p<0.0001) 3
However, a critical safety concern exists: Lamotrigine has been reported to induce OCD symptoms in some bipolar patients, with onset 2-8 months after initiation 4. This paradoxical effect resolved within one month of discontinuation in most cases.
Olanzapine Augmentation
The evidence for olanzapine is weak and contradictory:
- Two small open-label case series (n=10 each) showed mixed results: 40-44% response rates 5, 6
- Major concern: 60% of patients experienced significant weight gain 6
- Notably, quetiapine (similar atypical antipsychotic) was inferior to fluoxetine plus placebo in the only head-to-head RCT 1
- A 2019 network meta-analysis found olanzapine became significant only after baseline severity adjustment 7
The Combination (Lamotrigine + Olanzapine)
No studies have evaluated this specific combination for OCD. The FDA label for olanzapine lists approved indications as schizophrenia and bipolar disorder only—not OCD 8.
Clinical Algorithm for Treatment-Resistant OCD
Confirm adequate first-line trial: SSRI at maximum dose for 8-12 weeks 1
Second-line options (choose based on availability and patient factors):
- Add CBT with exposure and response prevention (if available and patient can tolerate)
- Switch to different SSRI or clomipramine
- Consider SNRI trial 1
Third-line augmentation (if above strategies fail):
Monitor closely:
- With antipsychotics: weight, metabolic parameters
- With lamotrigine: paradoxical worsening of obsessions (rare but reported) 4
- Avoid olanzapine given weak evidence and high metabolic risk
Bottom Line
If you're considering lamotrigine specifically, it has reasonable evidence as monotherapy augmentation (100mg dose) 2, 3. Adding olanzapine to this regimen lacks any supporting evidence and adds substantial metabolic risk without proven benefit for OCD. The combination appears to be based on extrapolation rather than data. If antipsychotic augmentation is needed after lamotrigine trial, risperidone or aripiprazole would be more evidence-based choices 1, 7.